Glaucoma Market - Forecast ,Growth, Region Wise Analysis , Top Players, Application, Drivers by 2026

Glaucoma is a common, asymptomatic group of eye diseases that causes damage to the eye’s optic nerve, resulting in progressive, irreversible vision loss. Glaucoma is one of the leading causes of blindness worldwide, especially in elderly people. Glaucoma is generally categorized as open-angle glaucoma (OAG), angle-closure glaucoma (ACG), or secondary glaucoma (SG), though other less common types exist. OAG and ACG can be classified as primary (primary open-angle glaucoma [POAG] or primary angle-closure glaucoma [PACG], respectively) or SG, depending on the cause.

Request a sample of this report @ http://orbisresearch.com/contacts/request-sample/2043274 

To forecast the total prevalent cases of POAG, PACG, NTG, PPG, and SG in the 7MM, GlobalData epidemiologists selected nationally representative, population-based studies that provided these epidemiological data in the 7MM. GlobalData epidemiologists obtained data for the diagnosed prevalent cases of PPG from primary market research and authentic secondary sources. In addition, the forecast is supported by robust, country-specific data that were obtained from various authentic sources, such as research articles published in peer-reviewed journals.

In the 7MM, the total prevalent cases of POAG will increase from 7,224,135 cases in 2016 to 8,549,547 cases in 2026, at an Annual Growth Rate (AGR) of 1.83%. In the 7MM, the total prevalent cases of PACG will increase from 2,644,012 cases in 2016 to 3,124,740 cases in 2026, at an AGR of 1.82%. GlobalData forecasts that all markets will see an increase in the total prevalent cases and diagnosed prevalent cases of POAG and PACG during the forecast period.

Scope
- The Glaucoma EpiCast Report provides an overview of the risk factors and global trends of glaucoma in the 7MM (US, France, Germany, Italy, Spain, UK, and Japan). It includes a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of primary open-angle glaucoma (POAG) or primary angle-closure glaucoma (PACG), segmented by sex and age (40-49 years, 50-59 years, 60-69 years, 70-79 years, and ages 80 years and older) in these markets. In addition, this report provides a 10-year epidemiological forecast for the total prevalent cases and diagnosed prevalent cases of glaucoma clinical types normal-tension glaucoma (NTG), pre perimetric glaucoma (PPG), and secondary glaucoma (SG). The report also includes the diagnosed incident cases of acute PACG.
- The glaucoma epidemiology report is written and developed by Masters- and PhD-level epidemiologists.
- The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 7MM.

Reasons to buy
The Glaucoma EpiCast report will allow you to -
- Develop business strategies by understanding the trends shaping and driving the global glaucoma market.
- Quantify patient populations in the global glaucoma market to improve product design, pricing, and launch plans.
- Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for glaucoma therapeutics in each of the markets covered.
- Understand the population of glaucoma clinical types NTG, PPG, and SG.

Browse the complete report @ http://orbisresearch.com/reports/index/epicast-report-glaucoma-epidemiology-forecast-to-2026 

List Of Tables:

1.1 List of Tables
Table 1: Risk Factors and Comorbidities for Glaucoma 10
Table 2: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 25
Table 3: 7MM, Diagnosed Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 28
Table 4: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 28
Table 5: 7MM, Diagnosed Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 31
Table 6: 7MM, Total Prevalent Cases of NTG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 31
Table 7: 7MM, Diagnosed Prevalent Cases of NTG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 32
Table 8: 7MM, Total Prevalent Cases of PPG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 33
Table 9: 7MM, Diagnosed Prevalent Cases of PPG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 34
Table 10: 7MM, Total Prevalent Cases of SG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 34
Table 11: 7MM, Diagnosed Prevalent Cases of SG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 35
Table 12: 7MM, Diagnosed Incident Cases of Acute PACG, Both Sexes, Ages ≥40 Years, N, Selected Years 2016-2026 36
Table 13: High-Prescribing Physicians (Non-KOLs), Surveyed by Country, 2017 40

1.2 List of Figures
Figure 1: 7MM, Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, 2016 and 2026 6
Figure 2: 7MM, Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, 2016 and 2026 7
Figure 3: 7MM, Age-Standardized Total Prevalence of POAG, Men and Women, Ages ≥40 Years, 2016 11
Figure 4: 7MM, Age-Standardized Total Prevalence of PACG, Men and Women, Ages ≥40 Years, 2016 12
Figure 5: 7MM, Sources Used to Forecast Total Prevalent Cases of POAG 13
Figure 6: 7MM, Sources Used to Forecast Total Prevalent Cases of PACG 14
Figure 7: 7MM, Sources Used to Forecast Total Prevalent Cases of NTG 15
Figure 8: 7MM, Sources Used to Forecast Total Prevalent Cases of PPG 16
Figure 9: 7MM, Sources Used to Forecast Total Prevalent Cases of SG 17
Figure 10: 7MM, Sources Used to Forecast Diagnosed Incident Cases of Acute PACG 17
Figure 11: 7MM, Age-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, 2016 26
Figure 12: 7MM, Sex-Specific Total Prevalent Cases of POAG, Both Sexes, Ages ≥40 Years, N, 2016 27
Figure 13: 7MM, Age-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, 2016 29
Figure 14: 7MM, Sex-Specific Total Prevalent Cases of PACG, Both Sexes, Ages ≥40 Years, N, 2016 30

Buy a report @ http://orbisresearch.com/contact/purchase/2043274